[go: up one dir, main page]

US3225091A - Anticholinergic substituted butyramides - Google Patents

Anticholinergic substituted butyramides Download PDF

Info

Publication number
US3225091A
US3225091A US170506A US17050662A US3225091A US 3225091 A US3225091 A US 3225091A US 170506 A US170506 A US 170506A US 17050662 A US17050662 A US 17050662A US 3225091 A US3225091 A US 3225091A
Authority
US
United States
Prior art keywords
butylamino
acid
diphenyl
butyramide
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US170506A
Inventor
Ainsworth Cameron
Charles W Ryan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Priority to US170506A priority Critical patent/US3225091A/en
Application granted granted Critical
Publication of US3225091A publication Critical patent/US3225091A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups

Definitions

  • t-hydrocarbyl generally contains 4 to 20 carbon atoms and the alkyl group from 1 to 4 carbon atoms.
  • the t-hydrocarbyl substituent is t-butyl or t-amyl. It is most significant that the presence of the t-hydrocarbyl moiety, directly bound to the nitrogen atom of the amino group, is prerequisite to the excellent anticholiner ic activity of the novel compounds of this invention. Replacement of the t-hydrocarbyl moiety with, for example, a propyl moiety results in drastically decreased anticholinergic activity.
  • R is a tertiary-hydrocarbon group containing 4 to 20 carbon atomspreferably, t-butyl or t-amyland R is an alkyl group containing 1 to 4 carbon atoms.
  • Exemplary of such salts are inorganic acid addition salts, such as the hydrochloride, monohydrosulfate, nitrate, phosphate, hydriodide, and the like, as well as organic acid salts, such as the acetate, maleate, tartrate, malate, pamoate (embinate), napsylate, tosylate, succinate, citrate, benzoate, stearate, and the like.
  • inorganic acid addition salts such as the hydrochloride, monohydrosulfate, nitrate, phosphate, hydriodide, and the like
  • organic acid salts such as the acetate, maleate, tartrate, malate, pamoate (embinate), napsylate, tosylate, succinate, citrate, benzoate, stearate, and the like.
  • Another embodiment of this invention is a method for inhibiting gastric secretion which comprises therapeutically administering an effective quantity of the novel compounds of this invention. Such therapeutic administration also results in inhibition of gastric motility and ICC gastrointestinal smooth muscle innervated by postganglionic cholinergic nerves.
  • a pharmaceutical composition wherein the improvement comprises a 2,2-diphenyl-4-(N-alkyl-t-hydrocarbylamino)butyramide is the vehicle for administration of the active compounds of this invention.
  • the form of the pharmaceutical composition can be adapted for oral or parenteral administration, oral administration being especially preferred because of the ease and convenience associated therewith.
  • the pharmaceutical compositions which comprise an embodiment of this invention can be in the form of a compressed tablet or a filled capsule, as well as in the form of a pharmaceutical solution or suspension suitable for oral or intramuscular administration.
  • novel butyramides of this invention are 2,2-diphenyl-4- (N-methyl-t-butylamino butyramide, 2,2-diphenyl-4-(N-ethyl-t-butylamino)butyramide, 2,2-diphenyl-4-(N-n-propyl-t-butylamino)butyramide, 2,2- diphenyl-4-(N-methyl-t-amylamino)-butyramide, and the like, as well as the corresponding hydrochloride, acetate, and the like acid addition salts of each of the foregoing.
  • Preferred because of exceptional anticholinergic properties is 2,2-diphenyl-4-(N-methyl-t-butylamino)butyramide hydrochloride.
  • Example I t-ButyIamin0ethan0l.-T0 a solution of 73 g. (1 mole) of t-butylamine in 200 ml. of methanol were added 44 g. (1 mole) of ethylene oxide. The mixture was allowed to stand overnight, and was then heated at reflux temperature for 30 minutes. The reaction product was fractionally distilled, and 67 g. (57 percent of theory) of tbutylaminoethanol were collected; boiling point, -75 C. (5 mm. Hg); melting point, 43 C.
  • reaction mixture was refluxed 18 additional hours. It was then cooled and 800 ml. of water were added.
  • the toluene layer was extracted with 1000 ml. of 2 N HCl, then with two 500 ml. portions of 2 N HCl.
  • the aqueous extracts were combined and cooled to C., whereupon a solid precipitated.
  • the solid was collected by filtration, washed with ether and dried, yielding 505 g. (94 percent of theory) of 2,2- diphenyl-4- (N-methyl-t-butylamino butyronitrile hydrochloride; melting point, 9397 C.
  • An analytical sample was recrystallized from acetone; melting point, 122- 124 C.
  • Example II 2-(N-ethyl-t-butylamino)ethanoL-A solution of 115 g. (1.14 moles) of N-ethyl-t-butylamine, 75 ml. of ethylene oxide, and 200 ml. of methanol was heated in a pressure reactor for 18 hours at 65 C. The reaction mixture was then distilled to obtain 137 g. (83 percent of theory) of 2-(N-ethyl-t-buty1amino)ethanol; boiling point, 72 75 C. (7 mm), N 1.4425.
  • the organic layer was washed with 100 ml. of 1 N hydrochloric acid. .
  • the resulting aqueous acid layer was separated, made basic, and then washed with two 50 ml. portions of benzene.
  • the benzene solution was dried with potassium carbonate and concentrated to yield 9 g. of crude 2,2-diphenyl-4- (N-ethyl-t-butylamino)butyronitrile. Without purification, the nitrile was dissolved in 55 ml. of percent sulfuric acid and heated on a steam bath for four hours. After being cooled, the solution was poured over ice and made basic with ammonium hydroxide. The basic solution was extracted with two ml. portions of chloroform.
  • the acid addition salts of the aminobutyramides of this invention are readily prepared by methods fully set forth in the prior art. For example, if a solid acid is to be employed in forming the acid addition salt, an equivalent of this acid, either as such or in solution, is added to a solution containing an equivalent of the aminobutyramide. If the acid addition salt thus formed is insoluble in the reaction solvent, the salt is isolated by filtration or centrifugation. On the other hand, if the salt is soluble in the reaction medium, it can be isolated by evaporation of the volatile constituents. When a gaseous acid, as, for example, hydrogen chloride, is employed, it is possible to use an excess of the acid since the excess can be readily removed by volatilization.
  • a gaseous acid as, for example, hydrogen chloride
  • acids which form acid addition salts with the aminobutyramides of this invention are inorganic acids including hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, hydriodic acid, and the like, as well as organic acids including acetic acid, maleic acid, citric acid, tartaric acid, malic acid, pamoic acid, naphthalensulfonic acid, p-toluene-sulfonic acid, succinic acid, benzoic acid, stearic acid, and the like.
  • the compounds of this invention may be prepared by the hydrolysis of the corresponding nitriles.
  • nitriles are prepared, for example, by condensing an alkyl-t-butylamine with a 2,2-diphenyl-4-halobutyronitrile; or a 2,2-diphenylacetonitrile can be condensed with an alkyl-t-butylaminoethyl halide (prepared, for example, by the method of Slotta and Behnisch, Ber. 68, 754 (1935)).
  • the techniques and information set forth in J. Organic Chemistry, vol. 17, pages 770-777 (1952) can be employed in the preparation of the novel butyramides of this invention.
  • Examples I and II set forth the preferred methods for the preparation of the compounds of this invention.
  • Example II employing the procedure of Example II-with the exception that 1.14 moles of N-n-propyl-bbutylamine are employed in place of the N-ethyl-t-butylamine utilized therein-2,2 diphenyl 4 (N-n-propyl-t-butylamino) butyramide is prepared.
  • 2,2-diphenyl-4-(N-nbutyl-t-butylamino)butyramide is prepared, employing the procedure of Example II, with the exception that 1.14
  • one or both of the phenyl groups at the 2 carbon position of the butyramides of this invention can be substituted with such groups as halo (i.e., chloro, bromo, iodo, fluoro) or alkyl containing 1 to 4 carbon atoms.
  • halo i.e., chloro, bromo, iodo, fluoro
  • alkyl containing 1 to 4 carbon atoms it is generally preferred that the phenyl substituents of the novel compounds of this invention be unsubstituted.
  • hydrocarbyl as employed herein signifies a hydrocarbon moiety bound to the nitrogen atom of the amino group of the amides of this invention through a tertiary carbon atom.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Description

United States Patent 3,225,091 ANricHoLiNERoic SUBSTITUTED BUTYRAMHDES Cameron Ainsworth and Charles W. Ryan, Indianapolis,
Ind., assignors to Eli Lilly and Company, Indianapolis, Ind., a corporation of Indiana No Drawing. Filed Feb. 1, 1962, Ser. No. 170,506
6 Claims. (Cl. 260558) C CH I CH(CH3)2 It is significant that, according to Speeter, the quaternary amine salt is necessary for significant therapeutic activity. To date, no tertiary-amino substituted amides have been disclosed having significant parasympathicolytic activity and, in particular, anticholinergic activity.
It is, therefore, an object of this invention to provide tertiary-amino substituted amides having such activity. It is also an object of this invention to provide methods for the preparation and therapeutic administration of said tertiary-amino amides.
These and other objects of this invention are accomplished by providing a 2,2-diphenyl-4-(N-alky1-t-hydrocarbylamino)-butyramide, wherein the t-hydrocarbyl generally contains 4 to 20 carbon atoms and the alkyl group from 1 to 4 carbon atoms. Preferably, the t-hydrocarbyl substituent is t-butyl or t-amyl. It is most significant that the presence of the t-hydrocarbyl moiety, directly bound to the nitrogen atom of the amino group, is prerequisite to the excellent anticholiner ic activity of the novel compounds of this invention. Replacement of the t-hydrocarbyl moiety with, for example, a propyl moiety results in drastically decreased anticholinergic activity.
The anticholinergic butyramides of this invention are more fully represented by the following general formula:
wherein R is a tertiary-hydrocarbon group containing 4 to 20 carbon atomspreferably, t-butyl or t-amyland R is an alkyl group containing 1 to 4 carbon atoms. Although the above formula is set forth in the form of the free base, it is to be understood that the acid addition salts thereof are included within the scope of the present invention. Exemplary of such salts are inorganic acid addition salts, such as the hydrochloride, monohydrosulfate, nitrate, phosphate, hydriodide, and the like, as well as organic acid salts, such as the acetate, maleate, tartrate, malate, pamoate (embinate), napsylate, tosylate, succinate, citrate, benzoate, stearate, and the like.
Another embodiment of this invention is a method for inhibiting gastric secretion which comprises therapeutically administering an effective quantity of the novel compounds of this invention. Such therapeutic administration also results in inhibition of gastric motility and ICC gastrointestinal smooth muscle innervated by postganglionic cholinergic nerves.
A pharmaceutical composition wherein the improvement comprises a 2,2-diphenyl-4-(N-alkyl-t-hydrocarbylamino)butyramide is the vehicle for administration of the active compounds of this invention. The form of the pharmaceutical composition can be adapted for oral or parenteral administration, oral administration being especially preferred because of the ease and convenience associated therewith. Thus, the pharmaceutical compositions which comprise an embodiment of this invention can be in the form of a compressed tablet or a filled capsule, as well as in the form of a pharmaceutical solution or suspension suitable for oral or intramuscular administration.
Representative of the novel butyramides of this invention are 2,2-diphenyl-4- (N-methyl-t-butylamino butyramide, 2,2-diphenyl-4-(N-ethyl-t-butylamino)butyramide, 2,2-diphenyl-4-(N-n-propyl-t-butylamino)butyramide, 2,2- diphenyl-4-(N-methyl-t-amylamino)-butyramide, and the like, as well as the corresponding hydrochloride, acetate, and the like acid addition salts of each of the foregoing. Preferred because of exceptional anticholinergic properties is 2,2-diphenyl-4-(N-methyl-t-butylamino)butyramide hydrochloride.
This invention is further represented by the following Working examples.
Example I t-ButyIamin0ethan0l.-T0 a solution of 73 g. (1 mole) of t-butylamine in 200 ml. of methanol were added 44 g. (1 mole) of ethylene oxide. The mixture was allowed to stand overnight, and was then heated at reflux temperature for 30 minutes. The reaction product was fractionally distilled, and 67 g. (57 percent of theory) of tbutylaminoethanol were collected; boiling point, -75 C. (5 mm. Hg); melting point, 43 C.
Z-(N-methyl-t-butylamino)ethanol hydrochloride.-A mixture of 67 g. (0.57 mole) of t-butylaminoethanol, 55 g. of 98 percent formic acid, and 51 g. of 37 percent aqueous formaldehyde was heated under reflux for four hours. The reaction product was acidified with 55 ml. of concentrated hydrochloric acid, and was evaporated to dryness under reduced pressure. The solid residue was crystallized from ml. of isopropyl alcohol, and 81 g. (85 percent of theory) of 2-(N-methyl-t--butylamino)- ethanol hydrochloride were obtained; melting point, -142 C.
Analysis.-Calculated for CqH1'7NO'HClI C, 50.14; H, 10.82; N, 8.36. Found: C, 49.89; H, 10.91; N, 8.18.
Z-(N-merhyl-t-butylamino)-1-chl0r0ethane hydrochloride.A solution of 295 g. (1.76 moles) of Z-(N-methylt-butylamino)-ethanol hydrochloride (produced as set forth above) and 600 ml. of chloroform was cooled in an ice bath and 450 g. of thionyl chloride were added. The reaction mixture was stirred for one hour, then heated under reflux for three hours. It was then concentrated under reduced pressure. The residue was recrystallized from an acetone-ether mixture. Total yield of 2-(N-methyl-t-butylamino)-1-ch1oroethane hydrochloride (first and second crops) was 291 g. (89 percent of theory).
Analysis.--Calculatcd for C7H15C1N'HC1Z C, 45.17; H, 9.21; N, 7.53. Found: C, 45.56; H, 8.91; N, 7.47. The free base, Z-(N-methyl-t-butylamino)-1-chloroethane, was obtained by treating the hydrochloride salt with potassium carbonate.
2,2 diplzenyll-(N-methyl-t-butylamino)butyronitrile hydr0chloride.-A suspension of 65 g. of sodium amide in 600 ml. of toluene was stirred and heated under reflux. A solution of 300 g. (1.55 moles) of diphenylacetonitrile in 1100 ml. of toluene was added, and the mixture was heated and stirred for four hours. To the hot suspension of the sodium salt of diphenylacetonitrile obtained thereby was added a solution of 1.56 moles of the free base, 2-(N-methyl-t-butylamino)-1-chloroethane in 500 ml. of toluene. The reaction mixture was refluxed 18 additional hours. It was then cooled and 800 ml. of water were added. The toluene layer was extracted with 1000 ml. of 2 N HCl, then with two 500 ml. portions of 2 N HCl. The aqueous extracts were combined and cooled to C., whereupon a solid precipitated. The solid was collected by filtration, washed with ether and dried, yielding 505 g. (94 percent of theory) of 2,2- diphenyl-4- (N-methyl-t-butylamino butyronitrile hydrochloride; melting point, 9397 C. An analytical sample was recrystallized from acetone; melting point, 122- 124 C.
Amrlysis.Calculated for C H N -HCl: C, 73.55; H, 7.93; N, 8.17. Found: C, 73.38; H, 7.79; N, 8.24.
2,2-diphenyl-4-(N-methyl-t-butylamino) butyramide. A solution of 400 g. (1.17 moles) of the above 2,2- diphenyl-4-(N-methyl-t-butylamino)butyronitrile hydrochloride and 715 ml. of 90 percent sulfuric acid was heated on the steam bath for five hours. The reaction mixture was cooled and poured over ice and made basic with ammonium hydroxide. The solid that precipitated was collected by filtration and dissolved in 2.5 liters of chloroform, and this solution was washed with water, dried with potassium carbonate, and concentrated under reduced pressure. The solid residue was recrystallized from methyl ethyl ketone, yielding 283 g. (74.3 percent of theory) of 2,2-diphenyl-4-(N-methyl-t-butylamino) butyramide; melting point, 178179 C.
Analysis.--Calculated for C H N O: C, 77.73; H, 8.70; N, 8.63. Found: C, 77.37; H, 8.70; N, 8.63.
2,2 dipheny[-4-(N-mezhyl-t-butylamino)bulyramide hydr0chl0ride.A suspension of 109 g. of 2,2-diphenyl- 4-(N-methyl-t-butylamino)butyramide in 700 ml. of isopropyl alcohol was stirred and HCl gas was added until the solids Went into solution. The solution was then filtered and diluted with 500 m1. of ether. After standing overnight, the solid that had precipitated was collected by filtration and recrystallized from isopropyl alcohol, yielding 105 g. (87 percent of theory) of 2,2- diphenyl-4-(N-methyl-t-butylarnino)butyramide hydrochloride; melting point, 235-236 C.
Example II 2-(N-ethyl-t-butylamino)ethanoL-A solution of 115 g. (1.14 moles) of N-ethyl-t-butylamine, 75 ml. of ethylene oxide, and 200 ml. of methanol was heated in a pressure reactor for 18 hours at 65 C. The reaction mixture was then distilled to obtain 137 g. (83 percent of theory) of 2-(N-ethyl-t-buty1amino)ethanol; boiling point, 72 75 C. (7 mm), N 1.4425.
Analysis.Calculated for C H1gNO: N, 9.64. Found: N, 9.69.
2 (N-ethyl-t-butylamin0)-Z-chl0r0ethane hydr0chl0- ride.A solution of 9.5 g. (0.065 mole) of Z-(N-ethylt-butylamino)-ethanol in 35 ml. of chloroform was made acidic by passing in HCl gas. The solution was then cooled in an ice bath and 20 ml. of thionyl chloride were added dropwise. After being stirred for two hours, the solution was heated under reflux for two hours. It was then concentrated and the residue was recrystallized from acetone-ether, yielding 8.8 g. (68 percent of theory) of 2-(N-ethyl-t-butylamino)-1-chloroethane hydrochloride; melting point, 166173 C.
Analysis-Calculated for C H -ClN-Hclz N, 7.00. Found: N, 7.01. This salt was neutralized to the free base by treating with potassium carbonate solution.
2,2-diphenyl-4-(N-ethyl-t-butylamino)butyramide. A suspension of 1.7 g. of sodium amide in 50 ml. of toluene was stirred and heated under reflux and a solution of 9 g. of diphenylacetonitrile in 100 ml. of toluene was added. After heating under reflux for an additional four hours, a solution of the above-prepared 2-(N-ethylt-butylamino)-1-chloroethane in 100 ml. of benzene was added, and the reaction mixture was stirred and heated under reflux for 18 hours. The reaction mixture was then cooled and diluted with 50 ml. of water. The organic layer was washed with 100 ml. of 1 N hydrochloric acid. .The resulting aqueous acid layer was separated, made basic, and then washed with two 50 ml. portions of benzene. The benzene solution was dried with potassium carbonate and concentrated to yield 9 g. of crude 2,2-diphenyl-4- (N-ethyl-t-butylamino)butyronitrile. Without purification, the nitrile was dissolved in 55 ml. of percent sulfuric acid and heated on a steam bath for four hours. After being cooled, the solution was poured over ice and made basic with ammonium hydroxide. The basic solution was extracted with two ml. portions of chloroform. The chloroform extracts were combined and dried with potassium carbonate, then concentrated under reduced pressure. A solid crystallized from the concentrate on standing and was recrystallized from cyclohexane and isopropanol-water to yield 4.4 g. (29 percent of theory) of 2,2-diphenyl-4-(N- ethyl-t-butylamino)butyramide; melting point, 107109 C.
2,2-diphenyl-4-(N-ethyl-t-buzylamino)butyramide hydr0chl0ride.-The hydrochloride salt was prepared by dissolving the free base in isopropanol, adding HCl gas until the solids dissolved, and then diluting with ether. The white crystalline solid which formed was recrystal lized from isopropanol to yield 2,2-diphenyl-4-(N-ethylt-butylamino)butyramide hydrochloride in 75 percent yield; melting point, 229-231 C.
The acid addition salts of the aminobutyramides of this invention are readily prepared by methods fully set forth in the prior art. For example, if a solid acid is to be employed in forming the acid addition salt, an equivalent of this acid, either as such or in solution, is added to a solution containing an equivalent of the aminobutyramide. If the acid addition salt thus formed is insoluble in the reaction solvent, the salt is isolated by filtration or centrifugation. On the other hand, if the salt is soluble in the reaction medium, it can be isolated by evaporation of the volatile constituents. When a gaseous acid, as, for example, hydrogen chloride, is employed, it is possible to use an excess of the acid since the excess can be readily removed by volatilization.
Among the acids which form acid addition salts with the aminobutyramides of this invention are inorganic acids including hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, hydriodic acid, and the like, as well as organic acids including acetic acid, maleic acid, citric acid, tartaric acid, malic acid, pamoic acid, naphthalensulfonic acid, p-toluene-sulfonic acid, succinic acid, benzoic acid, stearic acid, and the like.
In general, the compounds of this invention may be prepared by the hydrolysis of the corresponding nitriles. These nitriles are prepared, for example, by condensing an alkyl-t-butylamine with a 2,2-diphenyl-4-halobutyronitrile; or a 2,2-diphenylacetonitrile can be condensed with an alkyl-t-butylaminoethyl halide (prepared, for example, by the method of Slotta and Behnisch, Ber. 68, 754 (1935)). In general, the techniques and information set forth in J. Organic Chemistry, vol. 17, pages 770-777 (1952), can be employed in the preparation of the novel butyramides of this invention.
Examples I and II set forth the preferred methods for the preparation of the compounds of this invention. Thus, employing the procedure of Example II-with the exception that 1.14 moles of N-n-propyl-bbutylamine are employed in place of the N-ethyl-t-butylamine utilized therein-2,2 diphenyl 4 (N-n-propyl-t-butylamino) butyramide is prepared. Likewise, 2,2-diphenyl-4-(N-nbutyl-t-butylamino)butyramide is prepared, employing the procedure of Example II, with the exception that 1.14
5 moles of N-n-butyl-t-butylamine are utilized in place of the N-ethyl-t-butylamine.
In some cases, one or both of the phenyl groups at the 2 carbon position of the butyramides of this invention can be substituted with such groups as halo (i.e., chloro, bromo, iodo, fluoro) or alkyl containing 1 to 4 carbon atoms. However, it is generally preferred that the phenyl substituents of the novel compounds of this invention be unsubstituted.
Although the preparation of the novel amides of this invention has been illustrated by butyramides wherein the t-hydrocarbyl moiety directly bound to the nitrogen atom of the amino group is t-butyl, it is to be clearly understood that any t-hydrocarbyl group containing 4 to 20 carbon atoms and, preferably, 4 to 8 carbon atoms, can be employed. Illustrative of such hydrocarbyl groups are t-octyl [2(2,4,4-trimethylpentyl)], triphenylmethyl, 2(2- rnethylnonadecyl), and the like.
The term hydrocarbyl as employed herein signifies a hydrocarbon moiety bound to the nitrogen atom of the amino group of the amides of this invention through a tertiary carbon atom.
We claim:
1. 2,2-diphenyl-4-(N-n-a1kyl-t-hydrocarbylamino) butyramide wherein n-alkyl has from 1 to 4 carbon atoms and t-hydrocarbyl is a saturated C -C tertiary hydrocar bon radical.
2. An acid addition salt of a compound of claim 1 with a pharmaceutically acceptable acid.
3. 2,2-diphenyl-4-(N-methyl-t-butylamino)butyramide.
4. 2,2-diphenyl-4- (N-ethyl-t-butylamino)butyramide.
5. 2,2-diphenyl-4- N-methyl-tamy1amino butyramide.
6. 2,2 diphenyl-4-(N-methyl-t-butylamino)butyramide hydrochloride.
References Cited by the Examiner UNITED STATES PATENTS 2,823,233 2/1958 Specter 260558 2,841,589 7/1958 Brandstrom et a1. 260-558 2,884,436 4/1959 Janssen et a1 260-558 X 2,934,472 4/1960 May 167-55 2,999,790 9/1961 Alford 16755 FOREIGN PATENTS 790,102 2/ 1958 Great Britain.
89,981 2/1961 Denmark. 171,497 5/1960 Sweden.
IRVING MARCUS, Primary Examiner.
DUVAL T. MCCUTCHEN, NICHOLAS S. RIZZO,
WALTER A. MODANCE, Examiners.

Claims (2)

1. 2,2-DIPHENYL-4-(N-NALKYL-T-HYDROCARBYLAMINO)-BUTYRAMIDE WHEREIN N-ALKYL HAS FROM 1 TO 4 CARBON ATOMS AND T-HYDROCARBYL IS A SATURATED C4-C8 TERTIARY HYDROCARBON RADICAL.
2. AN ACID ADDITION SALT OF A COMPOUND OF CLAIM 1 WITH A PHARAMACEUTICALLY ACCEPTABLE ACID.
US170506A 1962-02-01 1962-02-01 Anticholinergic substituted butyramides Expired - Lifetime US3225091A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US170506A US3225091A (en) 1962-02-01 1962-02-01 Anticholinergic substituted butyramides

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US170506A US3225091A (en) 1962-02-01 1962-02-01 Anticholinergic substituted butyramides

Publications (1)

Publication Number Publication Date
US3225091A true US3225091A (en) 1965-12-21

Family

ID=22620118

Family Applications (1)

Application Number Title Priority Date Filing Date
US170506A Expired - Lifetime US3225091A (en) 1962-02-01 1962-02-01 Anticholinergic substituted butyramides

Country Status (1)

Country Link
US (1) US3225091A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3372177A (en) * 1964-08-17 1968-03-05 Bristol Myers Co Phenyltoloxamine aluminum pamoate
US4107205A (en) * 1977-03-11 1978-08-15 G. D. Searle & Co. α-Aryl-α,α-bis[ω-(disubstituted amino)alkyl]acetamides and related compounds
US4217306A (en) * 1978-05-01 1980-08-12 G. D. Searle & Co. α-Aryl-α,α-bis[ω-(disubstituted amino)alkyl]-acetamides
US4576786A (en) * 1983-12-21 1986-03-18 Westinghouse Electric Corp. Partial grid for a nuclear reactor fuel assembly

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB790102A (en) * 1955-06-20 1958-02-05 Upjohn Co Process for the preparation of tertiaryamino substituted amides
US2823233A (en) * 1954-03-08 1958-02-11 Bristol Lab Inc Quaternary salts of substituted diphenylalkanoic acid amides
US2841589A (en) * 1958-07-01 Alpha-aryl
US2884436A (en) * 1954-08-28 1959-04-28 Nl Combinatie Chem Ind Parasympathicolytically active alpha, alpha-diphenyl-gamma-dialkylaminobutyramide compounds and manufacture thereof
US2934472A (en) * 1958-01-13 1960-04-26 Dow Corning Process for relieving human gas pains with methylpolysiloxane
US2999790A (en) * 1959-08-24 1961-09-12 Sterling Drug Inc Stable aluminum hydroxide suspension
DK89981A (en) * 1980-03-01 1981-09-02 T B Stamp APPLICATION FOR USE IN CASTING OF ACCUMULATOR PLATE GUITARS

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2841589A (en) * 1958-07-01 Alpha-aryl
US2823233A (en) * 1954-03-08 1958-02-11 Bristol Lab Inc Quaternary salts of substituted diphenylalkanoic acid amides
US2884436A (en) * 1954-08-28 1959-04-28 Nl Combinatie Chem Ind Parasympathicolytically active alpha, alpha-diphenyl-gamma-dialkylaminobutyramide compounds and manufacture thereof
GB790102A (en) * 1955-06-20 1958-02-05 Upjohn Co Process for the preparation of tertiaryamino substituted amides
US2934472A (en) * 1958-01-13 1960-04-26 Dow Corning Process for relieving human gas pains with methylpolysiloxane
US2999790A (en) * 1959-08-24 1961-09-12 Sterling Drug Inc Stable aluminum hydroxide suspension
DK89981A (en) * 1980-03-01 1981-09-02 T B Stamp APPLICATION FOR USE IN CASTING OF ACCUMULATOR PLATE GUITARS

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3372177A (en) * 1964-08-17 1968-03-05 Bristol Myers Co Phenyltoloxamine aluminum pamoate
US4107205A (en) * 1977-03-11 1978-08-15 G. D. Searle & Co. α-Aryl-α,α-bis[ω-(disubstituted amino)alkyl]acetamides and related compounds
US4217306A (en) * 1978-05-01 1980-08-12 G. D. Searle & Co. α-Aryl-α,α-bis[ω-(disubstituted amino)alkyl]-acetamides
US4576786A (en) * 1983-12-21 1986-03-18 Westinghouse Electric Corp. Partial grid for a nuclear reactor fuel assembly

Similar Documents

Publication Publication Date Title
DE2901181C2 (en) N- (1-alkyl- or allyl-2-pyrrolidinylmethyl) -2-methoxy-4-amino-5-alkylsulfonylbenzamides, their salts, processes for their preparation and pharmaceuticals containing them
US4675319A (en) Antianaphylactic and antibronchospastic piperazinyl-(N-substituted phenyl)carboxamides, compositions and use
US4146637A (en) Anti-inflammatory n-acyl substituted benzamides
US4112234A (en) Imidazolylmethylthioethyl alkynyl guanidines
JPS5919549B2 (en) Heterocyclic compounds
US3225091A (en) Anticholinergic substituted butyramides
Wuest et al. Some Derivatives of 3-Pyridol with Parasympathomimetic Properties1
US4621088A (en) N-acyl derivatives of amino acids and their esters, and drugs in which they are present
PL175707B1 (en) Novel 1-aryloxy-3-alkylamine 2-propanol esters and pharmaceutical agent
US3254120A (en) N-(tertiaryaminoalkoxy-benzoyl) anilides
US4183930A (en) Amino derivatives of pyrazolo [1,5-a]s-triazine, and their therapeutic applications
NO157931B (en) ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE 2- (4- (DIPHENYLMETHYLENE) -1-PIPERIDINYL) ACETIC ACIDS AND THEIR AMIDS AND SALTS.
DE2623075A1 (en) SUBSTITUTED BENZAMIDES
US4297357A (en) N-Phenethylacetamide compounds and process for preparation thereof
US3530137A (en) Certain alkyl and aryl ethers and thioethers of tropine and derivatives thereof
US4310532A (en) Methods and piperidinyl-alkyl-benzamide composition for inhibiting H2 histamine receptors
US3536723A (en) P - (2 - alkyloxy - benzoyl) - aminobenzoates of n - dialkylamine - alkyl and their quaternary salts
US3202674A (en) Phenethylamine derivatives
US4420482A (en) 1,4-Bis(acetylsalicyloyloxy)piperizine derivatives
GB1598628A (en) Guanidine derivatives
US3184467A (en) Gkanatanol-(j beta)-estees
DE2855853C2 (en) N- (1-Benzyl-2-methyl-3-pyrrolidinyl) -5-chloro-2-methoxy-4-methylaminobenzamide, its acid addition salts, process for their preparation and their use
US3663610A (en) Amidine derivatives with spasmolytic,psychostimulant and anorexigenic properties
US3787436A (en) 2-(diphenyl amino-alkyl amino)-2-imidazolines
US3712893A (en) Butyl-piperazine derivatives